Creo Medical Limited
CREO.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £4,000 | £30,800 | £27,169 | £25,161 |
| % Growth | -87% | 13.4% | 8% | – |
| Cost of Goods Sold | £2,100 | £15,500 | £17,160 | £16,138 |
| Gross Profit | £1,900 | £15,300 | £10,009 | £9,023 |
| % Margin | 47.5% | 49.7% | 36.8% | 35.9% |
| R&D Expenses | £11,100 | £11,800 | £13,527 | £12,869 |
| G&A Expenses | £30,300 | £40,500 | £43,929 | £41,544 |
| SG&A Expenses | £30,300 | £40,500 | £27,289 | £26,113 |
| Sales & Mktg Exp. | £0 | £0 | -£16,640 | -£15,431 |
| Other Operating Expenses | -£10,700 | -£12,200 | £0 | £0 |
| Operating Expenses | £30,700 | £40,100 | £40,816 | £38,982 |
| Operating Income | -£28,800 | -£24,800 | -£30,807 | -£29,959 |
| % Margin | -720% | -80.5% | -113.4% | -119.1% |
| Other Income/Exp. Net | -£200 | £500 | -£200 | -£380 |
| Pre-Tax Income | -£29,000 | -£24,500 | -£30,977 | -£30,339 |
| Tax Expense | -£1,200 | -£2,800 | -£4,041 | -£5,744 |
| Net Income | -£28,700 | -£21,700 | -£26,936 | -£24,595 |
| % Margin | -717.5% | -70.5% | -99.1% | -97.8% |
| EPS | -0.079 | -0.069 | -0.14 | -0.14 |
| % Growth | -14.6% | 50.5% | 0% | – |
| EPS Diluted | -0.079 | -0.069 | -0.14 | -0.14 |
| Weighted Avg Shares Out | 361,669 | 313,004 | 187,895 | 170,381 |
| Weighted Avg Shares Out Dil | 361,664 | 313,004 | 187,895 | 170,381 |
| Supplemental Information | – | – | – | – |
| Interest Income | £200 | £700 | £34 | £31 |
| Interest Expense | £400 | £400 | £248 | £363 |
| Depreciation & Amortization | £2,500 | £3,400 | £3,113 | £2,562 |
| EBITDA | -£26,100 | -£20,700 | -£27,616 | -£27,540 |
| % Margin | -652.5% | -67.2% | -101.6% | -109.5% |